2-羟基-3-(1H-咪唑-2-基)丙酸 | 30581-88-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-羟基-3-(1H-咪唑-2-基)丙酸
• 英文名称: 2-hydroxy-3-(1H-imidazol-2-yl)propanoic acid
• CAS: 30581-88-5
• 化学式: C₆H₈N₂O₃
• 分子量: 156.14
• InChiKey: YJZRJGAMMDSUEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  86.2
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• ACID-SENSITIVE LINKERS FOR DRUG DELIVERY
  申请人：Yang Jerry

  公开号：US20110053878A1

  公开（公告）日：2011-03-03

  The invention is in general directed to acid-sensitive linkers, and methods of use thereof, such as, for example, in drug delivery methods.

  本发明总体而言是指向对酸敏感的连接剂，以及它们的使用方法，例如，例如在药物传递方法中。
• PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS
  申请人：Philippe Michel

  公开号：US20100028280A1

  公开（公告）日：2010-02-04

  The invention relates to a process for straightening keratin fibres, comprising: (i) a step in which a straightening composition containing at least two denaturing agents is applied to the keratin fibres, (ii) a step in which the temperature of the keratin fibres is raised, using a heating means, to a temperature of between 110 and 250° C.

  该发明涉及一种直发角蛋白纤维的拉直过程，包括：(i)将至少两种变性剂含有的拉直组合物涂抹到角蛋白纤维上的步骤，(ii)使用加热装置将角蛋白纤维的温度升高至110至250°C的步骤。
• [EN] ACYLPIPERAZINES AS INHIBITORS OF TRANSGLUTAMINASE AND THEIR USE IN MEDICINE<br/>[FR] ACYL-PIPERAZINES EN TANT QU'INHIBITEURS DE LA TRANSGLUTAMINASE ET LEUR UTILISATION EN MÉDECINE
  申请人：UNIV ASTON

  公开号：WO2014057266A1

  公开（公告）日：2014-04-17

  The present invention relates to novel compounds of Formula I capable of inhibiting tissue transglutaminase, and uses of the same in medicine. In particular, the invention provides compounds for use in the treatment of prevention of disease and conditions such as fibrosis (e.g. cystic fibrosis), scarring, neurodegenerative diseases (e.g. Alzheimer's disease, Huntington's disease and Parkinson's disease), autoimmune diseases (e.g. multiple sclerosis and coeliac disease), thrombosis, proliferative disorders (e.g. cancers), AIDS, psoriasis and inflammation (e.g. chronic inflammatory diseases).

  本发明涉及一种能够抑制组织转谷氨酰胺酶的化合物I式新化合物，以及在医学上的用途。具体而言，该发明提供了用于治疗或预防疾病和病况的化合物，如纤维化（例如囊性纤维化）、瘢痕形成、神经退行性疾病（例如阿尔茨海默病、亨廷顿病和帕金森病）、自身免疫疾病（例如多发性硬化症和乳糜泻）、血栓形成、增生性疾病（例如癌症）、艾滋病、银屑病和炎症（例如慢性炎症性疾病）的化合物。
• [EN] NEW COMPOUNDS AND USES THEREOF<br/>[FR] NOUVEAUX COMPOSÉS ET LEURS UTILISATIONS
  申请人：BIOSTATUS LTD

  公开号：WO2014023956A1

  公开（公告）日：2014-02-13

  The present invention provides an anthraquinone compound of formula I (such as the compounds of formulae II to X) and processes for making the same. The invention further provides pharmaceutical compositions for use in the treatment of cancer, optionally in combination with an agent capable of reducing the level of oxygenation of a tumour. Additionally the invention provides an option for combination with chemotherapeutic and radiotherapeutic modalities to enhance overall tumour cell kill. The invention additionally provides methods for the detection of cellular hypoxia, both in vivo and in vitro.

  本发明提供了一种公式I的蒽醌化合物（例如公式II至X的化合物）及其制备方法。该发明还提供了用于治疗癌症的药物组合物，可选择地与能够降低肿瘤氧化水平的药物一起使用。此外，该发明提供了与化疗和放疗模式结合的选择，以增强整体肿瘤细胞杀伤效果。该发明还提供了用于检测细胞缺氧的方法，无论是在体内还是体外。
• GLP-1 PRODRUGS
  申请人：Novo Nordisk A/S

  公开号：US20150045281A1

  公开（公告）日：2015-02-12

  The invention relates to a GLP-1 prodrug of the general formula I: R1-(NHXaa1)-Xaa2-(OHis)-(GLP-1 peptide) (Formula I), wherein GLP-1 peptide is GLP-1(8-37) (SEQ ID NO: 1) or an analogue thereof having a maximum of nine amino acid changes as compared to GLP-1(8-37), R1 is lower alkyl, (NHXaa1) is an amino acid, Xaa2 is an amino acid, and (OHis) is a radical of imidazole-lactic acid; or a pharmaceutically acceptable salt, amide, or ester of the prodrug. The invention also relates to specific GLP-1 parent drugs of the general formula II: (HOHis)-(GLP-1 peptide) (Formula II), as well as specific intermediate products. The invention furthermore relates to a method of achieving release in vivo of an active and stabilised GLP-1 parent drug of the general formula II: (HOHis)-(GLP-1 peptide), by administering a GLP-1 prodrug; as well as to such GLP-1 prodrug, and such GLP-1 parent drug, respectively, for use as a medicament, in particular for use in the treatment and/or prevention of all forms of diabetes and related diseases. The prodrug may be used to alter the PK and/or absorption profile of the drug, for example to a desirable bell-shaped curve. The parent drug has a good biological activity, and is stabilised against degradation by DPP-IV.

  该发明涉及通式I的GLP-1前药：R1-(NHXaa1)-Xaa2-(OHis)-(GLP-1肽)（通式I），其中GLP-1肽是GLP-1(8-37)（序列ID号：1）或其类似物，与GLP-1(8-37)相比最多具有九个氨基酸变化，R1是较低的烷基，(NHXaa1)是一种氨基酸，Xaa2是一种氨基酸，(OHis)是咪唑乳酸的基团；或者是该前药的药用盐、酰胺或酯。该发明还涉及通式II的特定GLP-1母药：(HOHis)-(GLP-1肽)（通式II），以及特定的中间产物。此外，该发明还涉及通过给予GLP-1前药来在体内释放通式II的活性和稳定的GLP-1母药的方法：(HOHis)-(GLP-1肽)，以及用作药物的该GLP-1前药和该GLP-1母药，特别是用于治疗和/或预防所有形式的糖尿病和相关疾病。该前药可用于改变药物的PK和/或吸收特性，例如使其呈现理想的钟形曲线。母药具有良好的生物活性，并且受到DPP-IV的降解稳定性的保护。